DK1960387T3 - Isoquinolin- og benzo[h]isoquinolinderivater, fremstilling deraf og terapeutisk anvendelse deraf som antagonister af histamin H3-receptoren - Google Patents

Isoquinolin- og benzo[h]isoquinolinderivater, fremstilling deraf og terapeutisk anvendelse deraf som antagonister af histamin H3-receptoren

Info

Publication number
DK1960387T3
DK1960387T3 DK06829734.0T DK06829734T DK1960387T3 DK 1960387 T3 DK1960387 T3 DK 1960387T3 DK 06829734 T DK06829734 T DK 06829734T DK 1960387 T3 DK1960387 T3 DK 1960387T3
Authority
DK
Denmark
Prior art keywords
isoquinoline
histamine
benzo
antagonists
receptor
Prior art date
Application number
DK06829734.0T
Other languages
English (en)
Inventor
Martin Juan Antonio Diaz
Arenales Beatriz Escribano
Bargueno Maria Dolores Jimenez
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK1960387T3 publication Critical patent/DK1960387T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK06829734.0T 2005-11-24 2006-11-22 Isoquinolin- og benzo[h]isoquinolinderivater, fremstilling deraf og terapeutisk anvendelse deraf som antagonister af histamin H3-receptoren DK1960387T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111248A EP1790646A1 (fr) 2005-11-24 2005-11-24 Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
PCT/EP2006/012246 WO2007060027A1 (fr) 2005-11-24 2006-11-22 Derives de isoquinoline et benzo[h]isoquinoline, leur preparation et leur utilisation en therapeutique en tant qu’antagonistes du recepteur de l’histamine h3

Publications (1)

Publication Number Publication Date
DK1960387T3 true DK1960387T3 (da) 2012-02-27

Family

ID=36295552

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06829734.0T DK1960387T3 (da) 2005-11-24 2006-11-22 Isoquinolin- og benzo[h]isoquinolinderivater, fremstilling deraf og terapeutisk anvendelse deraf som antagonister af histamin H3-receptoren

Country Status (24)

Country Link
US (1) US7678807B2 (da)
EP (2) EP1790646A1 (da)
JP (1) JP5165578B2 (da)
KR (1) KR101386318B1 (da)
CN (1) CN101312961B (da)
AR (1) AR057615A1 (da)
AT (1) ATE531707T1 (da)
AU (1) AU2006316706B2 (da)
BR (1) BRPI0618971A2 (da)
CA (1) CA2630655C (da)
CY (1) CY1112386T1 (da)
DK (1) DK1960387T3 (da)
DO (1) DOP2006000253A (da)
ES (1) ES2376894T3 (da)
GT (1) GT200600490A (da)
IL (1) IL191214A (da)
PE (1) PE20070827A1 (da)
PL (1) PL1960387T3 (da)
PT (1) PT1960387E (da)
RU (1) RU2418794C2 (da)
SI (1) SI1960387T1 (da)
TW (1) TW200738681A (da)
UY (1) UY29971A1 (da)
WO (1) WO2007060027A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP2569296A1 (en) * 2010-05-11 2013-03-20 Sanofi Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
TW201202251A (en) 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
JP2013529198A (ja) * 2010-05-11 2013-07-18 サノフイ 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002904T2 (tr) * 1998-04-10 2001-02-21 Japan Tobacco Inc. Amidin bileşikleri
WO2000023437A1 (en) * 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogenous fused heterocycle compounds, process for the preparation thereof and agents containing the same
CZ20021911A3 (cs) * 1999-12-03 2002-10-16 Kyoto Pharmaceutical Industries, Ltd. Nové heterocyklické sloučeniny a jejich soli a jejich vyuľití v lékařství
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
NL1020155C2 (nl) * 2002-03-11 2003-09-17 Bernardus Johannes Jos Bekkers Inrichting voor het dragen van een golftas alsmede werkwijze voor het vervaardigen ervan.
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
AU2003256793A1 (en) * 2002-08-20 2004-03-11 Eli Lilly And Company Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique

Also Published As

Publication number Publication date
CA2630655C (fr) 2014-08-26
UY29971A1 (es) 2007-06-29
HK1126200A1 (en) 2009-08-28
IL191214A (en) 2012-07-31
BRPI0618971A2 (pt) 2011-09-20
SI1960387T1 (sl) 2012-03-30
CY1112386T1 (el) 2015-12-09
US7678807B2 (en) 2010-03-16
EP1960387A1 (fr) 2008-08-27
KR20080076910A (ko) 2008-08-20
AU2006316706A1 (en) 2007-05-31
US20080269199A1 (en) 2008-10-30
RU2418794C2 (ru) 2011-05-20
RU2008125136A (ru) 2009-12-27
AR057615A1 (es) 2007-12-05
CN101312961A (zh) 2008-11-26
PE20070827A1 (es) 2007-08-17
PT1960387E (pt) 2012-02-09
JP2009517357A (ja) 2009-04-30
EP1790646A1 (fr) 2007-05-30
ATE531707T1 (de) 2011-11-15
ES2376894T3 (es) 2012-03-20
WO2007060027A1 (fr) 2007-05-31
CN101312961B (zh) 2012-04-11
TW200738681A (en) 2007-10-16
PL1960387T3 (pl) 2012-03-30
GT200600490A (es) 2007-07-06
JP5165578B2 (ja) 2013-03-21
EP1960387B1 (fr) 2011-11-02
CA2630655A1 (fr) 2007-05-31
AU2006316706B2 (en) 2012-05-03
KR101386318B1 (ko) 2014-04-17
DOP2006000253A (es) 2007-07-15

Similar Documents

Publication Publication Date Title
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
IL189499A (en) Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist
BRPI0508263B8 (pt) derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
DK2069342T3 (da) Derivater af 2-aryl-6-phenyl-imidazol[1,2-A]pyridiner, fremstilling og terapeutisk anvendelse deraf
NO20055238D0 (no) Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister
DK1539742T3 (da) Indolderivater, der er nyttige som histamin H3-antagonister
DK1761519T3 (da) Indolderivater som histaminreceptorantagonister
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DK1811999T3 (da) Quinuclidinderivater og deres anvendelse som muskariniske M3-receptor-antagonister
ATE415400T1 (de) Pyrazolopyridinderivate
DK2146991T3 (da) Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
ATE412651T1 (de) Pyrrolopyridinderivate
DK1943242T3 (da) Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer
IL179424A0 (en) Substituted oxazole -benzoisothiazole dioxide derivatives, process for their preparation and their use
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DK1636206T3 (da) Imidazolderivater som glutamatreceptorantagonister
DK1773796T3 (da) Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
DK2287163T3 (da) 2-amino-3-sulfonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidinantagonister af serotonin 5-ht6-receptorer, fremgangsmåder til fremstillingen og anvendelse deraf
EP1961753A4 (en) PYRAZOLOPYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister